Julien Edeline - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

2018 The Lancet Oncology 2448 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,185
Institution: Centre Eugène Marquis

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-8289-7741

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.